Intuitive Surgical Company Profile (NASDAQ:ISRG)

About Intuitive Surgical (NASDAQ:ISRG)

Intuitive Surgical logoIntuitive Surgical, Inc. (Intuitive) designs, manufactures and markets da Vinci Surgical Systems, and related instruments and accessories. The Company's da Vinci Surgical System consists of a surgeon's console, a patient-side cart and a vision system. The da Vinci Surgical System translates a surgeon's hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. The da Vinci Surgical System provides its operating surgeons with control, range of motion, tissue manipulation capability and three-dimensional (3-D), high-definition (HD) vision. Intuitive has four generations of da Vinci Surgical System: the da Vinci Xi Surgical System, the da Vinci Si Surgical System, the da Vinci S Surgical System and the standard da Vinci Surgical System. The Company's instruments and accessories include EndoWrist Instruments and da Vinci Single-Site.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:ISRG
  • CUSIP: 46120E60
  • Web:
  • Market Cap: $40.52264 billion
  • Outstanding Shares: 111,452,000
Average Prices:
  • 50 Day Moving Avg: $347.28
  • 200 Day Moving Avg: $310.58
  • 52 Week Range: $203.57 - $367.50
  • Trailing P/E Ratio: 50.80
  • Foreward P/E Ratio: 47.90
  • P/E Growth: 4.02
Sales & Book Value:
  • Annual Revenue: $2.87 billion
  • Price / Sales: 13.73
  • Book Value: $40.63 per share
  • Price / Book: 8.70
  • EBITDA: $1.08 billion
  • Net Margins: 28.44%
  • Return on Equity: 15.99%
  • Return on Assets: 14.06%
  • Current Ratio: 4.41%
  • Quick Ratio: 4.05%
  • Average Volume: 350,830 shs.
  • Beta: 0.39
  • Short Ratio: 4.68

Frequently Asked Questions for Intuitive Surgical (NASDAQ:ISRG)

What is Intuitive Surgical's stock symbol?

Intuitive Surgical trades on the NASDAQ under the ticker symbol "ISRG."

When did Intuitive Surgical's stock split? How did Intuitive Surgical's stock split work?

Intuitive Surgical's stock split on Friday, October 6th 2017. The 3-1 split was announced on Friday, August 11th 2017. The newly minted shares were distributed to shareholders after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of Intuitive Surgical stock prior to the split would have 300 shares after the split.

How were Intuitive Surgical's earnings last quarter?

Intuitive Surgical, Inc. (NASDAQ:ISRG) released its earnings results on Thursday, July, 20th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $756.20 million for the quarter, compared to the consensus estimate of $724.51 million. Intuitive Surgical had a net margin of 28.44% and a return on equity of 15.99%. Intuitive Surgical's quarterly revenue was up 12.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.62 earnings per share. View Intuitive Surgical's Earnings History.

When will Intuitive Surgical make its next earnings announcement?

Intuitive Surgical is scheduled to release their next quarterly earnings announcement on Thursday, October, 19th 2017. View Earnings Estimates for Intuitive Surgical.

Where is Intuitive Surgical's stock going? Where will Intuitive Surgical's stock price be in 2017?

16 brokers have issued 12-month target prices for Intuitive Surgical's stock. Their predictions range from $75.00 to $353.33. On average, they expect Intuitive Surgical's stock price to reach $139.91 in the next year. View Analyst Ratings for Intuitive Surgical.

What are analysts saying about Intuitive Surgical stock?

Here are some recent quotes from research analysts about Intuitive Surgical stock:

  • 1. According to Zacks Investment Research, "Over the last three months, Intuitive Surgical was trading consistently ahead of the broader industry. While a stellar second-quarter 2017 result was a major market sentiment booster, the company gained significantly on the CE Mark approval for da Vinci X in Europe. The stock has got a further boost on the recent U.S. FDA approval of the same. A positive outlook for the coming quarters also raises our confidence in the stock. Further, incremental spending on product development and higher investments in international markets are prudent moves that are likely to drive long-term growth. The company is also expected to enhance its organizational capabilities and gain prominence in the markets of Europe and Asia. However, the da Vinci Surgical System has a long sale and purchase order cycle which might act against the company. In fact, the stock looks a tad expensive, adding to our concerns." (7/25/2017)
  • 2. Cantor Fitzgerald analysts commented, "Procedure growth: Guidance for 2017 procedure growth appears to be conservative. ISRG had 17% procedure growth in the 1H and is guiding to 14-15% procedure growth for 2017, implying 11-13% procedure growth in the 2H. The first-half procedure growth came in above expectations, as gynecology (grew in low single digits) and urology (grew in mid-to-high single digits) and China (grew by well over 25%) outpaced expectations. Second-half guidance assumes slower growth in gynecology, urology, and China, one less selling day in 3Q, and lower growth in Japan due to a lack of reimbursement." (7/21/2017)
  • 3. Canaccord Genuity analysts commented, "Our checks at the SAGES conference in Houston this week reaffirmed our near-term bullishness about the firm's fundamentals. A year ago coming out of this important trade show, we opined that a robotics revolution was underway in general surgery;our checks at SAGES 2017 suggest the revolution continues ' especially in hernia repair. Given the large opportunity open to robotic surgery ' nearly 1M annual hernia procedures in the U.S. of which nearly 70% are currently performed via an invasive, open surgery ' we discerned escalating enthusiasm from robotic surgeons. In sum, we think ISRG is positioned well to deliver procedure volume growth at or above its current guidance, which calls for 9-12% growth in 2017. On the competitive front, Medtronic looks to be at least a few years out, but seems to be ISRG's most imminent challenger. At an analyst meeting during SAGES yesterday, Medtronic updated its projections for entry into the surgical robotics arena, targeting initial market entry into a few small countries in Europe before the end of F2018 (April '18). Further, Medtronic expects FDA approval, as well as market expansion into larger European markets, during its F2019, with material revenue contributions expected over that timeframe. Meanwhile, we think ISRG (the company and the stock) still has room to run. We maintain our BUY rating and $800 price target." (3/24/2017)

Who are some of Intuitive Surgical's key competitors?

Who are Intuitive Surgical's key executives?

Intuitive Surgical's management team includes the folowing people:

  • Lonnie M. Smith, Independent Chairman of the Board
  • Gary S. Guthart Ph.D., President, Chief Executive Officer, Director
  • Marshall L. Mohr, Chief Financial Officer, Senior Vice President
  • Salvatore J. Brogna, Executive Vice President - Product Operations
  • David J. Rosa, Executive Vice President, Chief Commercial Officer
  • Mark J. Meltzer, Senior Vice President, Chief Compliance Officer, General Counsel
  • Myriam J. Curet M.D., Senior Vice President, Chief Medical Officer
  • Jamie E. Samath, Vice President, Corporate Controller, and Principal Accounting Officer
  • Alan J. Levy Ph.D., Lead Independent Director
  • Craig H. Barratt Ph.D., Independent Director

Who owns Intuitive Surgical stock?

Intuitive Surgical's stock is owned by a number of of institutional and retail investors. Top institutional investors include Bath Savings Trust Co (0.00%) and Eqis Capital Management Inc. (0.00%). Company insiders that own Intuitive Surgical stock include Alan J Levy, Amal M Johnson, Colin Morales, Curet Myriam, David J Rosa, Eric H Halvorson, Gary S Guthart, George Stalk Jr, Jamie Samath, Keith R Leonard, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman and Salvatore Brogna. View Institutional Ownership Trends for Intuitive Surgical.

Who sold Intuitive Surgical stock? Who is selling Intuitive Surgical stock?

Intuitive Surgical's stock was sold by a variety of institutional investors in the last quarter, including Bath Savings Trust Co. Company insiders that have sold Intuitive Surgical stock in the last year include Alan J Levy, Amal M Johnson, Colin Morales, Curet Myriam, David J Rosa, Gary S Guthart, Jamie Samath, Keith R Leonard, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman and Salvatore Brogna. View Insider Buying and Selling for Intuitive Surgical.

Who bought Intuitive Surgical stock? Who is buying Intuitive Surgical stock?

Intuitive Surgical's stock was bought by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for Intuitive Surgical.

How do I buy Intuitive Surgical stock?

Shares of Intuitive Surgical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intuitive Surgical's stock price today?

One share of Intuitive Surgical stock can currently be purchased for approximately $353.47.

MarketBeat Community Rating for Intuitive Surgical (NASDAQ ISRG)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  514 (Vote Outperform)
Underperform Votes:  430 (Vote Underperform)
Total Votes:  944
MarketBeat's community ratings are surveys of what our community members think about Intuitive Surgical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Intuitive Surgical (NASDAQ:ISRG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.69)
Consensus Price Target: $139.91 (60.42% downside)
Consensus Price Target History for Intuitive Surgical (NASDAQ:ISRG)
Price Target History for Intuitive Surgical (NASDAQ:ISRG)
Analysts' Ratings History for Intuitive Surgical (NASDAQ:ISRG)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
10/10/2017WedbushReiterated RatingBuyN/AView Rating Details
9/5/2017Morgan StanleyReiterated RatingOverweightHighView Rating Details
9/1/2017Royal Bank Of CanadaReiterated RatingHold$333.33N/AView Rating Details
7/26/2017Canaccord GenuityReiterated RatingHold$96.67 -> $111.11LowView Rating Details
7/24/2017Citigroup Inc.Reiterated RatingBuy$101.89 -> $119.78LowView Rating Details
7/22/2017Stifel NicolausReiterated RatingBuy$94.44 -> $122.22MediumView Rating Details
7/21/2017J P Morgan Chase & CoReiterated RatingOverweight$116.67HighView Rating Details
7/21/2017Barclays PLCBoost Price TargetOverweight$96.67 -> $111.11HighView Rating Details
7/21/2017Cantor FitzgeraldReiterated RatingHold$116.67HighView Rating Details
7/5/2017Leerink SwannReiterated RatingOutperformMediumView Rating Details
6/15/2017BTIG ResearchReiterated RatingHoldLowView Rating Details
6/1/2017Bank of America CorporationReiterated RatingBuy$111.11LowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageBuy -> Buy$111.11MediumView Rating Details
4/25/2017Jefferies Group LLCReiterated RatingBuy$75.00LowView Rating Details
4/19/2017Evercore ISIBoost Price TargetIn-Line$83.33 -> $87.22LowView Rating Details
8/26/2016Raymond James Financial, Inc.Initiated CoverageOutperformN/AView Rating Details
7/21/2016Northland SecuritiesDowngradeMarket Perform -> Under Perform$66.67N/AView Rating Details
7/20/2016Piper Jaffray CompaniesReiterated RatingNeutral$67.78 -> $77.78N/AView Rating Details
4/14/2016Sterne Agee CRTReiterated RatingNeutralN/AView Rating Details
1/22/2016William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Intuitive Surgical (NASDAQ:ISRG)
Earnings by Quarter for Intuitive Surgical (NASDAQ:ISRG)
Earnings History by Quarter for Intuitive Surgical (NASDAQ ISRG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/20/2017Q2 2017$0.64$0.66$724.51 million$756.20 millionViewN/AView Earnings Details
4/18/2017Q1 17$0.44$0.57$664.72 million$674.20 millionViewN/AView Earnings Details
1/24/2017Q416$0.67$0.68$739.65 million$757.00 millionViewN/AView Earnings Details
10/18/2016Q3$0.57$0.69$650.49 million$682.90 millionViewListenView Earnings Details
7/19/2016Q216$0.55$0.62$640.69 million$670.00 millionViewListenView Earnings Details
4/19/2016Q1$0.48$0.49$593.08 million$594.50 millionViewListenView Earnings Details
1/21/2016Q4$0.56$0.65$655.32 million$676.50 millionViewListenView Earnings Details
10/20/2015Q3$0.47$0.58$580.37 million$590.00 millionViewListenView Earnings Details
7/21/2015Q2$0.44$0.51$566.86 million$586.10 millionViewListenView Earnings Details
4/21/2015Q1$0.32$0.40$535.10 million$532.10 millionViewListenView Earnings Details
1/22/2015Q4$0.38$0.46$599.17 million$604.70 millionViewListenView Earnings Details
10/21/2014Q314$0.30$0.44$515.44 million$550.00 millionViewListenView Earnings Details
7/22/2014Q214$0.31$0.31$502.23 million$512.00 millionViewListenView Earnings Details
4/22/2014Q114$0.37$0.30$507.04 million$464.70 millionViewListenView Earnings Details
1/23/2014Q413$0.42$0.48$576.00 million$576.20 millionViewListenView Earnings Details
10/17/2013Q313$0.38$0.44$525.47 million$499.00 millionViewListenView Earnings Details
7/18/2013Q2 2013$0.45$0.43$594.58 million$578.50 millionViewListenView Earnings Details
4/18/2013Q1 2013$0.45$0.51$583.59 million$611.40 millionViewListenView Earnings Details
1/22/2013Q4 2012$0.45$0.47$584.36 million$609.30 millionViewListenView Earnings Details
10/16/2012$0.39$0.50ViewN/AView Earnings Details
7/19/2012$0.40$0.42ViewN/AView Earnings Details
4/17/2012$0.35$0.39ViewN/AView Earnings Details
1/19/2012$0.37$0.42ViewN/AView Earnings Details
10/18/2011$0.31$0.34ViewN/AView Earnings Details
7/19/2011$0.30$0.32ViewN/AView Earnings Details
4/19/2011$0.28$0.29ViewN/AView Earnings Details
1/20/2011$0.25$0.34ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intuitive Surgical (NASDAQ:ISRG)
2017 EPS Consensus Estimate: $15.35
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$3.96$3.96$3.96
Q2 20171$4.55$4.55$4.55
Q3 20171$4.89$4.89$4.89
Q4 20171$1.95$1.95$1.95
(Data provided by Zacks Investment Research)


Dividend History for Intuitive Surgical (NASDAQ:ISRG)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Intuitive Surgical (NASDAQ:ISRG)
Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 31.41%
Insider Trades by Quarter for Intuitive Surgical (NASDAQ:ISRG)
Institutional Ownership by Quarter for Intuitive Surgical (NASDAQ:ISRG)
Insider Trades by Quarter for Intuitive Surgical (NASDAQ:ISRG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017Mark J MeltzerSVPSell500$1,025.00$512,500.00View SEC Filing  
9/1/2017Salvatore BrognaEVPSell899$1,001.90$900,708.10View SEC Filing  
8/31/2017Keith R LeonardDirectorSell854$1,000.00$854,000.00View SEC Filing  
8/22/2017Mark J MeltzerSVPSell500$982.90$491,450.00View SEC Filing  
7/27/2017Gary S GuthartCEOSell17,975$937.27$16,847,428.25View SEC Filing  
7/25/2017Curet MyriamSVPSell1,202$950.20$1,142,140.40View SEC Filing  
7/25/2017Jamie SamathVPSell242$949.01$229,660.42View SEC Filing  
7/25/2017Michael A FriedmanDirectorSell1,000$945.60$945,600.00View SEC Filing  
6/12/2017Mark J MeltzerSVPSell3,000$887.09$2,661,270.00View SEC Filing  
6/8/2017Mark J RubashDirectorSell3,000$931.51$2,794,530.00View SEC Filing  
6/7/2017Curet MyriamSVPSell750$930.00$697,500.00View SEC Filing  
6/5/2017Curet MyriamSVPSell2,644$921.26$2,435,811.44View SEC Filing  
6/5/2017Jamie SamathVPSell1,946$921.26$1,792,771.96View SEC Filing  
6/1/2017Salvatore BrognaEVPSell1,306$915.09$1,195,107.54View SEC Filing  
5/31/2017Amal M JohnsonDirectorSell1,000$917.27$917,270.00View SEC Filing  
5/5/2017Jamie SamathVPSell48$850.00$40,800.00View SEC Filing  
5/2/2017Curet MyriamSVPSell3,385$837.21$2,833,955.85View SEC Filing  
4/27/2017Marshall MohrCFOSell8,950$835.89$7,481,215.50View SEC Filing  
4/25/2017Jamie SamathVPSell626$825.00$516,450.00View SEC Filing  
4/24/2017Alan J LevyDirectorSell1,386$813.15$1,127,025.90View SEC Filing  
4/21/2017David J. RosaEVPSell5,000$810.52$4,052,600.00View SEC Filing  
4/21/2017Gary S GuthartCEOSell18,775$810.33$15,213,945.75View SEC Filing  
4/21/2017Jamie SamathVPSell490$811.67$397,718.30View SEC Filing  
4/21/2017Lonnie M SmithDirectorSell3,000$810.12$2,430,360.00View SEC Filing  
3/15/2017Amal M JohnsonDirectorSell1,000$750.00$750,000.00View SEC Filing  
3/15/2017David J RosaEVPSell5,000$750.00$3,750,000.00View SEC Filing  
3/15/2017Jamie SamathVPSell4,268$750.00$3,201,000.00View SEC Filing  
3/15/2017Marshall MohrCFOSell4,250$750.00$3,187,500.00View SEC Filing  
3/1/2017Salvatore BrognaEVPSell6,628$736.80$4,883,510.40View SEC Filing  
2/24/2017Curet MyriamSVPSell222$729.80$162,015.60View SEC Filing  
2/21/2017Mark J MeltzerSVPSell8,750$724.82$6,342,175.00View SEC Filing  
2/7/2017Colin MoralesSVPSell1,000$703.99$703,990.00View SEC Filing  
2/2/2017Marshall MohrCFOSell2,000$700.00$1,400,000.00View SEC Filing  
1/27/2017Lonnie M SmithDirectorSell1,000$684.38$684,380.00View SEC Filing  
12/13/2016David J RosaEVPSell7,200$650.00$4,680,000.00View SEC Filing  
12/13/2016Lonnie M SmithDirectorSell1,000$650.00$650,000.00View SEC Filing  
11/17/2016Lonnie M SmithDirectorSell275$646.50$177,787.50View SEC Filing  
11/7/2016Gary S GuthartCEOSell13,515$680.68$9,199,390.20View SEC Filing  
8/22/2016Mark J MeltzerSVPSell3,000$688.33$2,064,990.00View SEC Filing  
8/4/2016Alan J LevyDirectorSell3,188$694.11$2,212,822.68View SEC Filing  
8/1/2016Gary S GuthartCEOSell13,400$698.00$9,353,200.00View SEC Filing  
7/27/2016Curet MyriamSVPSell4,250$684.39$2,908,657.50View SEC Filing  
7/27/2016Marshall MohrCFOSell5,000$684.09$3,420,450.00View SEC Filing  
6/2/2016Salvatore BrognaEVPSell600$630.96$378,576.00View SEC Filing  
6/1/2016Salvatore BrognaEVPSell20,406$632.66$12,910,059.96View SEC Filing  
5/17/2016Curet MyriamSVPSell530$629.36$333,560.80View SEC Filing  
5/17/2016Lonnie M SmithDirectorSell2,000$627.23$1,254,460.00View SEC Filing  
5/3/2016George Stalk JrDirectorSell7,644$618.70$4,729,342.80View SEC Filing  
5/2/2016Marshall MohrCFOSell5,000$631.63$3,158,150.00View SEC Filing  
4/27/2016Mark J MeltzerSVPSell16,625$631.52$10,499,020.00View SEC Filing  
4/26/2016Alan J LevyDirectorSell542$631.72$342,392.24View SEC Filing  
4/25/2016Amal M JohnsonDirectorSell2,500$640.00$1,600,000.00View SEC Filing  
4/22/2016Curet MyriamSVPSell8,173$637.75$5,212,330.75View SEC Filing  
4/22/2016Eric H HalvorsonDirectorSell5,688$639.21$3,635,826.48View SEC Filing  
3/14/2016Eric H HalvorsonDirectorSell4,438$593.16$2,632,444.08View SEC Filing  
3/14/2016Mark J MeltzerSVPSell12,500$589.00$7,362,500.00View SEC Filing  
3/11/2016Curet MyriamSVPSell2,000$582.50$1,165,000.00View SEC Filing  
3/11/2016Jamie SamathVPSell8,026$575.95$4,622,574.70View SEC Filing  
3/10/2016Alan J LevyDirectorSell5,000$569.14$2,845,700.00View SEC Filing  
3/7/2016Colin MoralesSVPSell2,500$575.00$1,437,500.00View SEC Filing  
3/4/2016Colin MoralesSVPSell884$571.49$505,197.16View SEC Filing  
3/3/2016Marshall MohrCFOSell2,500$575.00$1,437,500.00View SEC Filing  
3/2/2016Salvatore BrognaEVPSell1,882$567.37$1,067,790.34View SEC Filing  
2/19/2016Colin MoralesSVPSell5,530$542.83$3,001,849.90View SEC Filing  
2/4/2016Curet MyriamSVPSell2,000$551.00$1,102,000.00View SEC Filing  
2/4/2016Marshall MohrCFOSell2,500$550.00$1,375,000.00View SEC Filing  
1/29/2016Mark J. MeltzerSVPSell4,125$527.59$2,176,308.75View SEC Filing  
12/14/2015Salvatore BrognaEVPSell2,734$530.00$1,449,020.00View SEC Filing  
11/20/2015Mark J. MeltzerSVPSell1,625$515.00$836,875.00View SEC Filing  
10/26/2015Mark J. MeltzerSVPSell2,500$498.37$1,245,925.00View SEC Filing  
10/23/2015Lonnie M. SmithDirectorSell10,328$500.00$5,164,000.00View SEC Filing  
9/1/2015Salvatore BrognaEVPSell374$501.99$187,744.26View SEC Filing  
8/18/2015George Stalk JrDirectorSell4,726$532.03$2,514,373.78View SEC Filing  
7/27/2015Gary S GuthartCEOSell17,255$541.98$9,351,864.90View SEC Filing  
7/27/2015Mark J MeltzerSVPSell4,750$542.03$2,574,642.50View SEC Filing  
7/24/2015David J RosaEVPSell2,800$550.20$1,540,560.00View SEC Filing  
7/24/2015Jamie SamathVPSell5,000$550.00$2,750,000.00View SEC Filing  
7/24/2015Lonnie M SmithDirectorSell20,000$544.62$10,892,400.00View SEC Filing  
6/9/2015Alan J LevyDirectorSell417$495.41$206,585.97View SEC Filing  
6/8/2015Gary S GuthartCEOSell17,840$492.16$8,780,134.40View SEC Filing  
5/29/2015Lonnie M SmithDirectorSell2,000$488.68$977,360.00View SEC Filing  
5/27/2015Curet MyriamSVPSell1,000$489.35$489,350.00View SEC Filing  
5/18/2015Colin MoralesSVPSell13,824$503.29$6,957,480.96View SEC Filing  
4/28/2015Curet MyriamSVPSell261$504.54$131,684.94View SEC Filing  
4/27/2015Jerome J McnamaraEVPSell15,000$504.06$7,560,900.00View SEC Filing  
4/27/2015Marshall MohrCFOSell10,000$504.08$5,040,800.00View SEC Filing  
4/24/2015Lonnie M SmithDirectorSell20,000$508.03$10,160,600.00View SEC Filing  
3/2/2015Salvatore BrognaSVPSell1,375$500.98$688,847.50View SEC Filing  
2/6/2015Mark J RubashDirectorSell5,000$520.00$2,600,000.00View SEC Filing  
1/27/2015Jerome J McnamaraEVPSell15,000$511.32$7,669,800.00View SEC Filing  
1/27/2015Lonnie M SmithDirectorSell20,000$511.31$10,226,200.00View SEC Filing  
1/27/2015Marshall MohrCFOSell5,000$511.14$2,555,700.00View SEC Filing  
12/8/2014Lonnie M SmithDirectorSell1,700$511.24$869,108.00View SEC Filing  
12/1/2014Salvatore BrognaSVPSell1,375$515.87$709,321.25View SEC Filing  
11/24/2014Colin MoralesSVPSell9,565$520.82$4,981,643.30View SEC Filing  
10/31/2014Marshall MohrCFOSell7,500$500.00$3,750,000.00View SEC Filing  
10/30/2014Floyd D Md LoopDirectorSell2,125$488.95$1,039,018.75View SEC Filing  
10/27/2014Floyd D Md LoopDirectorSell15,209$475.71$7,235,073.39View SEC Filing  
10/27/2014Jerome J McnamaraEVPSell15,000$473.76$7,106,400.00View SEC Filing  
10/27/2014Marshall MohrCFOSell2,500$473.50$1,183,750.00View SEC Filing  
9/2/2014Salvatore BrognaSVPSell12,626$472.06$5,960,229.56View SEC Filing  
8/26/2014Colin MoralesSVPSell4,105$478.66$1,964,899.30View SEC Filing  
7/28/2014Jerome J McnamaraEVPSell9,167$465.59$4,268,063.53View SEC Filing  
7/25/2014Colin MoralesSVPSell2,000$461.99$923,980.00View SEC Filing  
2/27/2014Colin MoralesSVPSell1,000$445.00$445,000.00View SEC Filing  
12/3/2012Lonnie M SmithChairmanSell1,000$525.98$525,980.00View SEC Filing  
9/4/2012Salvatore BrognaSVPSell1,250$490.25$612,812.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Intuitive Surgical (NASDAQ:ISRG)
Latest Headlines for Intuitive Surgical (NASDAQ:ISRG)
DateHeadline logoThe case for Intuitive Surgical - Motley Fool - October 17 at 12:33 AM logoIs Transenterix (NYSE: TRXC) Really A Threat To Intuitive Surgical ... - Benzinga - October 17 at 12:33 AM logoWhy TransEnterix Is Skyrocketing Today - October 16 at 7:28 PM logoSurgical robot maker buys $6M Durham building - October 16 at 7:28 PM logoIs Transenterix Really A Threat To Intuitive Surgical? - October 16 at 7:28 PM logoIntuitive Surgical, Inc. (ISRG) Rating Reiterated by Wells Fargo & Company - October 16 at 10:08 AM logoHead to Head Review: Intuitive Surgical (ISRG) vs. Its Competitors - October 14 at 4:14 AM logoWhat Is Intuitive Surgical Inc’s (ISRG) Share Price Doing? - October 14 at 12:56 AM logoCramer's lightning round: Zagg's got good swag - October 13 at 3:17 AM logoAnalysts’ Ratings for Intuitive Surgical before 3Q17 Earnings - October 13 at 3:16 AM logoIntuitive Surgical’s 3Q17 Revenue: Can It Beat the Estimates? - October 13 at 3:16 AM logoBrokers Offer Predictions for Intuitive Surgical, Inc.'s Q4 2017 Earnings (ISRG) - October 12 at 10:42 AM logoStrong Buy Ranking on Intuitive Surgical (ISRG) Shares Retained - - October 12 at 2:47 AM logoRobotics and Enterprise Automation: Market Analysis and Forecasts in United States by Application and Sector 2017 - 2022 - October 11 at 4:45 PM logoStrong Buy Ranking on Intuitive Surgical (ISRG) Shares Retained - October 10 at 11:18 AM logoMedical Automation Market to Gain From Rising Adoption Rate of Equipment: Million Insights - October 9 at 7:59 PM logoIntuitive Surgical, Inc. breached its 50 day moving average in a Bearish Manner : ISRG-US : October 9, 2017 - October 9 at 7:58 PM logoIntuitive Surgical, Inc. (ISRG) to Release Quarterly Earnings on Monday - October 9 at 1:32 AM
News IconWall St Week Ahead-Tax-cut plan prompts fund managers to bet on automation - October 7 at 12:00 AM logoIntuitive Surgical’s Recent Stock Split: The Market Reaction - October 6 at 11:59 PM logoIntuitive Surgical Traded at a 52-Week High on October 5 - October 6 at 11:59 PM logoWhat Analysts Recommend for Intuitive Surgical - October 6 at 11:59 PM logoIntuitive Surgical’s High Valuation: Is the Stock Overvalued? - October 6 at 11:59 PM logoCatch This Robotics Leader On The Upcoming Stock Split - Seeking Alpha - October 5 at 6:44 AM logoIf You're in Your 40s, Consider Buying This Stock - October 5 at 6:44 AM logoIf You Love Intuitive Surgical, You Should Check Out Mazor Robotics - October 2 at 7:30 AM logoIntuitive Surgical, Inc. (ISRG) Given Consensus Rating of "Buy" by Brokerages - October 1 at 2:38 PM logoThe Long-Term Trend That Makes Intuitive Surgical an Awesome Buy - October 1 at 7:57 AM logoDoes Intuitive Surgical Inc’s (ISRG) PE Ratio Warrant A Sell? - September 29 at 10:13 PM logoVarian Medical Initiates Treatment Using Halcyon System - September 29 at 9:52 AM logoIntuitive Surgical's (ISRG) Outperform Rating Reiterated at Wedbush - September 25 at 6:00 PM logoA Stellar Start for a Robotics ETF - Investopedia - September 20 at 11:39 PM logoOmega Flex, Inc. (OFLX) Ex-Dividend Date Scheduled for September 21, 2017 - Nasdaq - September 20 at 4:27 PM logoZimmer Biomet Holdings, Inc. (ZBH) Ex-Dividend Date Scheduled for September 21, 2017 - Nasdaq - September 20 at 4:27 PM logoA Stellar Start for a Robotics ETF - September 20 at 4:27 PM logoIntuitive Surgical, Inc. (ISRG) Shares Scheduled to Split on Friday, October 6th - September 20 at 1:22 AM logo3 Stocks to Hold for the Next Century - September 17 at 7:02 PM logoHow Much Higher Can Medtech Climb As Investors Flee Pharma? - September 15 at 2:13 AM logo4 Reasons to Buy Intuitive Surgical, Inc. Stock and Never Sell - Motley Fool - September 12 at 9:52 PM logoAnalysts have raised, or lowered, their price targets the most on these US stocks - MarketWatch - September 11 at 8:53 PM logo4 Reasons to Buy Intuitive Surgical, Inc. Stock and Never Sell - September 11 at 9:00 AM logoIs a Med-Tech Marriage in Mazor Robotics' Future? - September 10 at 5:49 AM logo$752.33 Million in Sales Expected for Intuitive Surgical, Inc. (ISRG) This Quarter - September 9 at 2:54 AM logoIntuitive Surgical Stock Just Set Another All-Time High: Is It Still a Buy? - Motley Fool - September 9 at 12:48 AM logoNoteworthy Wednesday Option Activity: FB, ADI, ISRG - Nasdaq - September 6 at 7:57 PM logoIntuitive Surgical Stock Just Set Another All-Time High: Is It Still a Buy? - September 6 at 3:13 PM logoIntuitive Surgical, Inc. (ISRG) Given Consensus Recommendation of "Buy" by Brokerages - September 6 at 2:36 PM logoMark J. Meltzer Sells 500 Shares of Intuitive Surgical, Inc. (ISRG) Stock - September 5 at 7:46 PM logoIntuitive Surgical Traded at Its 52-Week High on August 31 - September 4 at 6:52 PM logoStrategic Investments Drive Intuitive Surgical’s Future Growth - September 4 at 6:52 PM



Intuitive Surgical (ISRG) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.